Vivos Therapeutics (NASDAQ:VVOS) Lowered to “Hold” at Zacks Investment Research

Vivos Therapeutics (NASDAQ:VVOS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “

A number of other equities research analysts have also commented on the stock. Craig Hallum assumed coverage on shares of Vivos Therapeutics in a research note on Monday, January 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Roth Capital assumed coverage on shares of Vivos Therapeutics in a research note on Tuesday, January 5th. They issued a “buy” rating and a $12.00 price objective on the stock.

VVOS opened at $9.21 on Thursday. Vivos Therapeutics has a fifty-two week low of $5.64 and a fifty-two week high of $14.41. The stock’s 50 day simple moving average is $7.38.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Thursday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.27). The business had revenue of $3.30 million for the quarter, compared to analysts’ expectations of $2.92 million.

Large investors have recently bought and sold shares of the company. Royce & Associates LP acquired a new position in shares of Vivos Therapeutics during the 4th quarter valued at $1,773,000. K.J. Harrison & Partners Inc acquired a new position in shares of Vivos Therapeutics during the 4th quarter valued at $540,000. Walleye Capital LLC acquired a new position in shares of Vivos Therapeutics during the 4th quarter valued at $440,000. Jane Street Group LLC acquired a new position in shares of Vivos Therapeutics during the 4th quarter valued at $191,000. Finally, Perkins Capital Management Inc. acquired a new position in shares of Vivos Therapeutics during the 4th quarter valued at $118,000.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA.

Further Reading: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on Vivos Therapeutics (VVOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.